Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | NR3C1 | P04150 | 18/20 | 0.45 |
| ▸ | PGR | P06401 | 7/20 | 0.45 |
| ▸ | NR3C2 | P08235 | 7/20 | 0.45 |
| ▸ | AR | P10275 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4695856 | 0.94 | NR3C1 (0.48) | MEN1NPC1MAPTRAB9AKMT2A | |
| SCHEMBL4697274 | 0.94 | NR3C1 (0.44) | MEN1NPC1MAPTRAB9AKMT2A | |
| SCHEMBL4697677 | 0.93 | NR3C1 (0.47) | MEN1NPC1MAPTRAB9AKMT2A | |
| SCHEMBL4696723 | 0.92 | NR3C1 (0.43) | MEN1NPC1MAPTRAB9AKMT2A | |
| SCHEMBL4695624 | 0.91 | NR3C1 (0.51) | MEN1NPC1MAPTRAB9AKMT2A | |
| SCHEMBL4695634 | 0.91 | NR3C1 (0.42) | MEN1NPC1MAPTRAB9AKMT2A | |
| SCHEMBL4694685 | 0.91 | NR3C1 (0.42) | MEN1NPC1MAPTRAB9AKMT2A | |
| SCHEMBL4694709 | 0.91 | NR3C1 (0.44) | MEN1NPC1MAPTRAB9AKMT2A | |
| SCHEMBL4697276 | 0.90 | NR3C1 (0.42) | MEN1NPC1MAPTRAB9AKMT2A | |
| SCHEMBL5009707 | 0.89 | NR3C1 (0.42) | MEN1NPC1MAPTRAB9AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080292561-A1 | Pyrazolo-Pyrimidine Derivatives as Anti-Inflammatory Agents | GLAXO GROUP LIMITED | 2008-11-27 | — | — | US | claimed |
| EP-1945642-A1 | PYRAZOLO-PYRIMIDINE DERIVATIVES AS ANTI-INFLAMMATORY AGENTS | GLAXO GROUP LIMITED (GB) | 2008-07-23 | — | — | EP | claimed |
| WO-2007054294-A1 | PYRAZOLO-PYRIMIDINE DERIVATIVES AS ANTI-INFLAMMATORY AGENTS | GLAXO GROUP LIMITED (GB) | 2007-05-18 | — | — | WO | claimed |
| US-20080292561-A1 | Pyrazolo-Pyrimidine Derivatives as Anti-Inflammatory Agents | GLAXO GROUP LIMITED | 2008-11-27 | — | — | US | disclosed |
| US-20080292561-A1 | Pyrazolo-Pyrimidine Derivatives as Anti-Inflammatory Agents | GLAXO GROUP LIMITED | 2008-11-27 | — | — | US | disclosed |
| US-20080292561-A1 | Pyrazolo-Pyrimidine Derivatives as Anti-Inflammatory Agents | GLAXO GROUP LIMITED | 2008-11-27 | — | — | US | disclosed |
| EP-1945642-A1 | PYRAZOLO-PYRIMIDINE DERIVATIVES AS ANTI-INFLAMMATORY AGENTS | GLAXO GROUP LIMITED (GB) | 2008-07-23 | — | — | EP | disclosed |
| WO-2007054294-A1 | PYRAZOLO-PYRIMIDINE DERIVATIVES AS ANTI-INFLAMMATORY AGENTS | GLAXO GROUP LIMITED (GB) | 2007-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080292561-A1 | Pyrazolo-Pyrimidine Derivatives as Anti-Inflammatory Agents | NOD1, FPR3, FPR1 | MEN1 4703/4885NPC1 2006/4885MAPT 3829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.